Low Systemic Exposure after Repeated Topical Application of Pimecrolimus (Elidel®, SD Z ASM 981) in Patients with Atopic Dermatitis

Publisher： Karger

E-ISSN： 1421-9832|204|1|63-68

ISSN： 1018-8665

Source： Dermatology, Vol.204, Iss.1, 2002-04, pp. : 63-68

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Management of Atopic Eczema with Pimecrolimus Cream 1% (Elidel®) in Paediatric Patients

By  

Dermatology, Vol. 215, Iss. 1, 2007-12 ,pp. : 3-17

Karger

Access to resources Recommend Favorite

Significantly Elevated Systemic Levels after Occlusive Application of Topical Tacrolimus in Atopic Dermatitis

By  

Dermatology, Vol. 212, Iss. 3, 2006-04 ,pp. : 260-261

Karger

Access to resources Recommend Favorite

Occlusive Treatment of Chronic Hand Dermatitis with Pimecrolimus Cream 1% Results in Low Systemic Exposure, Is Well Tolerated, Safe, and Effective

By  

Dermatology, Vol. 207, Iss. 1, 2003-07 ,pp. : 37-42

Karger

Access to resources Recommend Favorite

Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial

By  

Dermatology, Vol. 222, Iss. 1, 2010-12 ,pp. : 36-48

Karger

Access to resources Recommend Favorite

The Role of Pimecrolimus Cream 1% (Elidel®) in Managing Adult Atopic Eczema

By  

Dermatology, Vol. 215, Iss. 1, 2007-12 ,pp. : 18-26

Karger

Access to resources Recommend Favorite